Update
$SAB Biotherapeutics(SABS.US$ SAB Biotherapeutics: on April 12, Completed Dosing of Cohort 3 for Phase One Trials of SAB-142, Has Not Observed Any Instances of Serum Sicknesses
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
